Early triple antiviral therapy for COVID-19
| Errataetall: |
CommentOn: Lancet. 2020 May 30;395(10238):1695-1704. - PMID 32401715 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:396 |
|---|---|
| Enthalten in: |
Lancet (London, England) - 396(2020), 10261 vom: 07. Nov., Seite 1487-1488 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lee, Nelson [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
145155-23-3 |
|---|
| Anmerkungen: |
Date Completed 20.11.2020 Date Revised 07.12.2022 published: Print CommentOn: Lancet. 2020 May 30;395(10238):1695-1704. - PMID 32401715 Citation Status MEDLINE |
|---|
| doi: |
10.1016/S0140-6736(20)32274-1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM317283529 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM317283529 | ||
| 003 | DE-627 | ||
| 005 | 20231225162931.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/S0140-6736(20)32274-1 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1057.xml |
| 035 | |a (DE-627)NLM317283529 | ||
| 035 | |a (NLM)33160566 | ||
| 035 | |a (PII)S0140-6736(20)32274-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lee, Nelson |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Early triple antiviral therapy for COVID-19 |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.11.2020 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a CommentOn: Lancet. 2020 May 30;395(10238):1695-1704. - PMID 32401715 | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Letter | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Comment | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a Interferon beta-1b |2 NLM | |
| 650 | 7 | |a 145155-23-3 |2 NLM | |
| 650 | 7 | |a Lopinavir |2 NLM | |
| 650 | 7 | |a 2494G1JF75 |2 NLM | |
| 650 | 7 | |a Ribavirin |2 NLM | |
| 650 | 7 | |a 49717AWG6K |2 NLM | |
| 650 | 7 | |a Ritonavir |2 NLM | |
| 650 | 7 | |a O3J8G9O825 |2 NLM | |
| 700 | 1 | |a Ison, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Dunning, Jake |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Lancet (London, England) |d 1945 |g 396(2020), 10261 vom: 07. Nov., Seite 1487-1488 |w (DE-627)NLM000473936 |x 1474-547X |7 nnns |
| 773 | 1 | 8 | |g volume:396 |g year:2020 |g number:10261 |g day:07 |g month:11 |g pages:1487-1488 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/S0140-6736(20)32274-1 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 396 |j 2020 |e 10261 |b 07 |c 11 |h 1487-1488 | ||